Re: Christoph A. Von Klot, Markus A. Kuczyk, Axel S. Merseburger. No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting. Eur Urol 2014;65:258-9: Enzalutamide withdrawal syndrome: fact or fiction?
暂无分享，去创建一个
[1] C. V. von Klot,et al. No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting. , 2014, European urology.
[2] Gang Shao,et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.
[3] Joshua M. Korn,et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.
[4] V. Arora,et al. Overcoming mutation-based resistance to antiandrogens with rational drug design , 2013, eLife.
[5] Chawnshang Chang,et al. Molecular basis for the antiandrogen withdrawal syndrome , 2004, Journal of cellular biochemistry.
[6] P. Schellhammer,et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. , 1997, The Journal of urology.